For: | Moreno-Cubero E, Larrubia JR. Specific CD8+ T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol 2016; 22(28): 6469-6483 [PMID: 27605882 DOI: 10.3748/wjg.v22.i28.6469] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v22/i28/6469.htm |
Number | Citing Articles |
1 |
Laura Wuyts, Annelies Janssens, Luisa Vonghia, Peter Michielsen, Jo Raskin, Ann Driessen, Stijn Van Hees, Sven Francque, Thomas Vanwolleghem. Nivolumab and anti-HCV activity, a case report. Acta Clinica Belgica 2021; 76(5): 392 doi: 10.1080/17843286.2020.1741897
|
2 |
Weifeng Yu, Yanjun Wang, Peng Guo. Notch signaling pathway dampens tumor-infiltrating CD8+ T cells activity in patients with colorectal carcinoma. Biomedicine & Pharmacotherapy 2018; 97: 535 doi: 10.1016/j.biopha.2017.10.143
|
3 |
Konstantinos Tsiakos, Niki Gavrielatou, Ioannis Vathiotis, Loukas Chatzis, Stamatios Chatzis, Garyfallia Poulakou, Elias Kotteas, Nikolaos Syrigos. Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities. Vaccines 2022; 10(10): 1673 doi: 10.3390/vaccines10101673
|
4 |
Emanuele Rinninella, Lucia Cerrito, Irene Spinelli, Marco Cintoni, Maria Cristina Mele, Maurizio Pompili, Antonio Gasbarrini. Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. Journal of Clinical and Translational Hepatology 2017; (XX): 1 doi: 10.14218/JCTH.2017.00002
|
5 |
Parbatraj Regmi, Zhi-Qiang He, Thongher Lia, Aliza Paudyal, Fu-Yu Li. N7-Methylguanosine Genes Related Prognostic Biomarker in Hepatocellular Carcinoma. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.918983
|
6 |
Y Liu, Y Cheng, Y Xu, Z Wang, X Du, C Li, J Peng, L Gao, X Liang, C Ma. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene 2017; 36(44): 6143 doi: 10.1038/onc.2017.209
|
7 |
Sharon Wei Ling Lee, Giulia Adriani, Erica Ceccarello, Andrea Pavesi, Anthony Tanoto Tan, Antonio Bertoletti, Roger Dale Kamm, Siew Cheng Wong. Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model. Frontiers in Immunology 2018; 9 doi: 10.3389/fimmu.2018.00416
|
8 |
Yaojie Fu, Shanshan Liu, Shan Zeng, Hong Shen. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1396-4
|
9 |
Zhen Tao, Hailong Ruan, Lin Sun, Dong Kuang, Yongchun Song, Qi Wang, Tao Wang, Yi Hao, Ke Chen. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity. Cancer Immunology Research 2019; 7(7): 1135 doi: 10.1158/2326-6066.CIR-18-0648
|
10 |
Xuefen Li, Xia Liu, Weilin Wang. IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.614847
|
11 |
Julia Peña-Asensio, Henar Calvo, Miguel Torralba, Joaquín Miquel, Eduardo Sanz-de-Villalobos, Juan-Ramón Larrubia. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers 2021; 13(8): 1922 doi: 10.3390/cancers13081922
|
12 |
Qian Li, Jingjing Han, Yonglin Yang, Yu Chen. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1070961
|
13 |
Dizhi Jiang, Xinyue Ma, Xun Zhang, Bo Cheng, Ruiqing Wang, Yuan Liu, Xinyu Zhang. New techniques: a roadmap for the development of HCC immunotherapy. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1121162
|
14 |
Monique T.A. de Beijer, Karel Bezstarosti, Robbie Luijten, Wouter A.S. Doff, Patrick P.C. Boor, Roel F.A. Pieterman, Rachid Bouzid, Paula J. Biesta, Jan N.M. Ijzermans, Michail Doukas, Robert A. de Man, Andrea M. Woltman, Jeroen A.A. Demmers, Sonja I. Buschow. Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma. JHEP Reports 2022; 4(11): 100576 doi: 10.1016/j.jhepr.2022.100576
|
15 |
Alex José de Melo Silva, Juliana Ellen de Melo Gama, Cleonilde Maria de Nascimento, Jessica Paula Lucena, Cicero Jadson da Costa, Camila Juliet Barbosa Fernandes, Danielle Maria Nascimento Moura, Helotonio Carvalho, Sheilla Andrade de Oliveira. Hepatobiliary Cancers: An Interdisciplinary Approach. Interdisciplinary Cancer Research 2022; 3: 85 doi: 10.1007/16833_2022_37
|
16 |
Shallu Tomer, SunilK Arora. A juggernaut of innate & adaptive immune cells in chronic hepatitis C. Indian Journal of Medical Research 2020; 151(4): 279 doi: 10.4103/ijmr.IJMR_1387_17
|
17 |
Mousumi Khatun, Ranjit Ray, Ratna B. Ray. Mechanisms and Therapy of Liver Cancer. Advances in Cancer Research 2021; 149: 103 doi: 10.1016/bs.acr.2020.10.003
|
18 |
Michelle Hong, Antonio Bertoletti. Viral Hepatitis in Children. 2019; : 115 doi: 10.1007/978-981-13-0050-9_8
|
19 |
Farhan Z. Ilyas, Joal D. Beane, Timothy M. Pawlik. The State of Immunotherapy in Hepatobiliary Cancers. Cells 2021; 10(8): 2096 doi: 10.3390/cells10082096
|
20 |
Ye Nie, Hanlu Fan, Jianhui Li, Xinjun Lei, Tianchen Zhang, Yanfang Wang, Zhenzhen Mao, Kaishan Tao, Wenjie Song. Tertiary lymphoid structures: Associated multiple immune cells and analysis their formation in hepatocellular carcinoma. The FASEB Journal 2022; 36(11) doi: 10.1096/fj.202200269RR
|
21 |
Siyuan Ma, Mengjiao Lv, Xiaohua Chen, Guoqing Zang, Zhenghao Tang, Yi Zhang, Weiwei Hu. Avasimibe can cooperate with a DC-targeting and integration-deficient lentivector to induce stronger HBV specific T cytotoxic response by regulating cholesterol metabolism. Antiviral Research 2023; 216: 105662 doi: 10.1016/j.antiviral.2023.105662
|
22 |
Caecilia H C Sukowati, Korri Elvanita El-Khobar, Claudio Tiribelli. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World Journal of Stem Cells 2021; 13(7): 795-824 doi: 10.4252/wjsc.v13.i7.795
|
23 |
João Panão Costa, Armando de Carvalho, Artur Paiva, Olga Borges. Insights into Immune Exhaustion in Chronic Hepatitis B: A Review of Checkpoint Receptor Expression. Pharmaceuticals 2024; 17(7): 964 doi: 10.3390/ph17070964
|
24 |
Banglun Pan, Zengbin Wang, Xiaoxia Zhang, Shuling Shen, Xiaoling Ke, Jiacheng Qiu, Yuxin Yao, Xiaoxuan Wu, Xiaoqian Wang, Nanhong Tang. Targeted inhibition of RBPJ transcription complex alleviates the exhaustion of CD8+ T cells in hepatocellular carcinoma. Communications Biology 2023; 6(1) doi: 10.1038/s42003-023-04521-x
|
25 |
Chenliang Zhou, Chaofan Li, Guo-Zhong Gong, Shuang Wang, Ji-Ming Zhang, Dao-Zhen Xu, Li-Min Guo, Hong Ren, Min Xu, Qing Xie, Chen Pan, Jie Xu, Zhongyu Hu, Shuang Geng, Xian Zhou, Xianzheng Wang, Xiaoyu Zhou, Haili Mi, Gan Zhao, Wencong Yu, Yu-Mei Wen, Lihua Huang, Xuan-Yi Wang, Bin Wang. Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients. Human Vaccines & Immunotherapeutics 2017; 13(9): 1989 doi: 10.1080/21645515.2017.1335840
|
26 |
Ziwei Li, Dongyu Duan, Li Li, Dan Peng, Yue Ming, Rui Ni, Yao Liu. Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1382256
|
27 |
Valli De Re, Maria Lina Tornesello, Mariangela De Zorzi, Laura Caggiari, Francesca Pezzuto, Patrizia Leone, Vito Racanelli, Gianfranco Lauletta, Laura Gragnani, Angela Buonadonna, Emanuela Vaccher, Anna Linda Zignego, Agostino Steffan, Franco M. Buonaguro. Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. Frontiers in Microbiology 2019; 10 doi: 10.3389/fmicb.2019.00475
|
28 |
Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. International Journal of Molecular Sciences 2021; 22(11): 5801 doi: 10.3390/ijms22115801
|
29 |
Valli De Re, Maria Lina Tornesello, Mariangela De Zorzi, Laura Caggiari, Francesca Pezzuto, Patrizia Leone, Vito Racanelli, Gianfranco Lauletta, Stefania Zanussi, Ombretta Repetto, Laura Gragnani, Francesca Maria Rossi, Riccardo Dolcetti, Anna Linda Zignego, Franco M. Buonaguro, Agostino Steffan. PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus‐related diseases. Liver International 2021; 41(1): 133 doi: 10.1111/liv.14667
|
30 |
Xiaoting Luo, Xin He, Xingmei Zhang, Xiaohui Zhao, Yuzhe Zhang, Yusheng Shi, Shengni Hua. Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy. MedComm 2024; 5(2) doi: 10.1002/mco2.474
|
31 |
Marcelo M. Rodríguez, Esteban Fiore, Juan Bayo, Catalina Atorrasagasti, Mariana García, Agostina Onorato, Luciana Domínguez, Mariana Malvicini, Guillermo Mazzolini. 4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12. Molecular Therapy 2018; 26(12): 2738 doi: 10.1016/j.ymthe.2018.09.012
|
32 |
Tasuku Nakabori, Yutaro Abe, Sena Higashi, Takeru Hirao, Yasuharu Kawamoto, Shingo Maeda, Kazuma Daiku, Makiko Urabe, Yugo Kai, Ryoji Takada, Takuo Yamai, Kenji Ikezawa, Hiroyuki Uehara, Kazuyoshi Ohkawa. Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection. JGH Open 2022; 6(5): 309 doi: 10.1002/jgh3.12737
|
33 |
Adane Adugna. Therapeutic strategies and promising vaccine for hepatitis C virus infection. Immunity, Inflammation and Disease 2023; 11(8) doi: 10.1002/iid3.977
|
34 |
Markus Bo Schoenberg, Xiaokang Li, Xinyu Li, Yongsheng Han, Nikolaus Börner, Dominik Koch, Markus Otto Guba, Jens Werner, Alexandr V. Bazhin. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review. International Immunopharmacology 2021; 101: 108220 doi: 10.1016/j.intimp.2021.108220
|
35 |
Michael J Grant, Nicholas DeVito, April K S Salama. Checkpoint Inhibitor use in Two Heart Transplant Patients with Metastatic Melanoma and Review of High-Risk Populations. Melanoma Management 2018; 5(4) doi: 10.2217/mmt-2018-0004
|
36 |
Jing Luan, Yuxin Liu, Meng Cao, Xianing Guo, Na Guo. The pathogenic response of cytotoxic T‑lymphocytes, a common therapeutic target for cancer, has a direct impact on treatment outcomes (Review). Oncology Reports 2024; 52(1) doi: 10.3892/or.2024.8757
|
37 |
Georgia Koutsoumpli, Oana Draghiciu, Hans W Nijman, Cesar Oyarce, Toos Daemen. Cancer Immunology. 2021; : 61 doi: 10.1007/978-3-030-50287-4_5
|
38 |
Yong Xu, Zehua Wang, Xianhong Du, Yuan Liu, Xiaojia Song, Tixiao Wang, Siyu Tan, Xiaohong Liang, Lifen Gao, Chunhong Ma. Tim‐3 blockade promotes iNKT cell function to inhibit HBV replication. Journal of Cellular and Molecular Medicine 2018; 22(6): 3192 doi: 10.1111/jcmm.13600
|
39 |
Yuanyuan Zheng, Yan Li, Jiao Feng, Jingjing Li, Jie Ji, Liwei Wu, Qiang Yu, Weiqi Dai, Jianye Wu, Yingqun Zhou, Chuanyong Guo. Cellular based immunotherapy for primary liver cancer. Journal of Experimental & Clinical Cancer Research 2021; 40(1) doi: 10.1186/s13046-021-02030-5
|
40 |
Lingzhen Hu, Zongren Wang, Yang Liao, Xiaomeng Jiang, Huojun Lian, Zhuoying Lin. Tumor-infiltrating T-Lymphocyte immunity-related immune tolerance and anti–programmed cell death protein 1/ligand of programmed cell death protein 1 therapy for advanced hepatocellular carcinoma. Oncology and Translational Medicine 2024; 10(4): 162 doi: 10.1097/ot9.0000000000000041
|
41 |
Gloria HJ Chan, Yong Xiang Gwee, Jia Li Low, Yiqing Huang, Zhi Yao Chan, Joan RE Choo, Natalie YL Ngoi, Yvonne LE Ang, Vaishnavi Muthu, Wan Qin Chong, Alvin Wong, Ross A. Soo. Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre. Lung Cancer 2020; 146: 145 doi: 10.1016/j.lungcan.2020.05.020
|
42 |
Wei Xu, Dongxu Zhao, Xiaowei Huang, Man Zhang, Minyue Yin, Lu Liu, Hongyu Wu, Zhen Weng, Chunfang Xu. The prognostic value and clinical significance of mitophagy-related genes in hepatocellular carcinoma. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.917584
|
43 |
Xiao-Xiao Ding, Qing-Ge Zhu, Shi-Ming Zhang, Lei Guan, Ting Li, Lei Zhang, Shi-Yang Wang, Wan-Li Ren, Xue-Mei Chen, Jing Zhao, Song Lin, Zhi-Zhen Liu, Yan-Xia Bai, Bing He, Hu-Qin Zhang. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget 2017; 8(33): 55715 doi: 10.18632/oncotarget.18382
|
44 |
Malini Manoharan, Nitin Mandloi, Sushri Priyadarshini, Ashwini Patil, Rohit Gupta, Laxman Iyer, Ravi Gupta, Amitabha Chaudhuri. A Computational Approach Identifies Immunogenic Features of Prognosis in Human Cancers. Frontiers in Immunology 2018; 9 doi: 10.3389/fimmu.2018.03017
|